Search

Your search keyword '"Wattel, Eric"' showing total 244 results
Start Over Author "Wattel, Eric" Publication Type Academic Journals
244 results on '"Wattel, Eric"'

2. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML

Author

Mohamed, Aminetou Mint, Balsat, Marie, Koering, Catherine, Maucort-Boulch, Delphine, Boissel, Nicolas, Payen-Gay, Lea, Cheok, Meyling, Mortada, Hussein, Auboeuf, Didier, Pinatel, Christiane, El-Hamri, Mohamed, Tigaud, Isabelle, Hayette, Sandrine, Dumontet, Charles, Cros, Emeline, Flandrin-Gresta, Pascale, Nibourel, Olivier, Preudhomme, Claude, Thomas, Xavier, Nicolini, Franck-Emmanuel, Solly, Françoise, Guyotat, Denis, Campos, Lydia, Michallet, Mauricette, Ceraulo, Antony, Mortreux, Franck, and Wattel, Eric

Published
2017
Full Text
View/download PDF

4. Endemic versus epidemic viral spreads display distinct patterns of HTLV-2b replication

Author

Gabet, Anne-Sophie, Moulés, Vincent, Sibon, David, Nass, Catharie C, Mortreux, Franck, Mauclère, Philippe, Gessain, Antoine, Murphy, Edward L, and Wattel, Eric

Subjects
Medical Microbiology, Biomedical and Clinical Sciences, Immunology, Rare Diseases, Infectious Diseases, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, 2.2 Factors relating to the physical environment, Infection, Good Health and Well Being, Adult, Blood Donors, Carrier State, Cell Proliferation, Child, DNA Fingerprinting, DNA, Viral, Endemic Diseases, Female, HTLV-II Infections, Human T-lymphotropic virus 2, Humans, Male, Middle Aged, Molecular Epidemiology, Polymerase Chain Reaction, Proviruses, Viral Load, Virus Replication, deltaretroviruses, HTLV, HTLV-2, HTLV-2b, epidemiology, genetic variability, clonal expansion, replication, leukemogenesis, Biological Sciences, Agricultural and Veterinary Sciences, Medical and Health Sciences, Virology, Agricultural, veterinary and food sciences, Biological sciences, Biomedical and clinical sciences
Abstract

As the replication pattern of leukemogenic PTLVs possesses a strong pathogenic impact, we investigated HTLV-2 replication in vivo in asymptomatic carriers belonging into 2 distinct populations infected by the same HTLV-2b subtype. They include epidemically infected American blood donors, in whom HTLV-2b has been present for only 30 years, and endemically infected Bakola Pygmies from Cameroon, characterized by a long viral endemicity (at least few generations). In blood donors, both the circulating proviral loads and the degree of infected cell proliferation were largely lower than those characterizing asymptomatic carriers infected with leukemogenic PTLVs (HTLV-1, STLV-1). This might contribute to explain the lack of known link between HTLV-2b infection and the development of malignancies in this population. In contrast, endemically infected individuals displayed high proviral loads resulting from the extensive proliferation of infected cells. The route and/or the duration of infection, viral genetic drift, host immune response, genetic background, co-infections or a combination thereof might have contributed to these differences between endemically and epidemically infected subjects. As the clonality pattern observed in endemically infected individuals is very reminiscent of that of leukemogenic PTLVs at the pre-leukemic stage, our results highlight the possible oncogenic effect of HTLV-2b infection in such population.

Published
2006

5. Cidofovir in the Treatment of BK Virus–Associated Hemorrhagic Cystitis after Allogeneic Hematopoietic Stem Cell Transplantation

Author

Philippe, Michael, Ranchon, Florence, Gilis, Lila, Schwiertz, Vérane, Vantard, Nicolas, Ader, Florence, Labussiere-Wallet, Hélène, Thomas, Xavier, Nicolini, Franck-Emmanuel, Wattel, Eric, Ducastelle-Leprêtre, Sophie, Barraco, Fiorenza, Lebras, Laure, Salles, Gilles, Michallet, Mauricette, and Rioufol, Catherine

Published
2016
Full Text
View/download PDF

17. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network.

Author

Itzykson, Raphael, Santini, Valeria, Thepot, Sylvain, Ades, Lionel, Chaffaut, Cendrine, Giagounidis, Aristoteles, Morabito, Margot, Droin, Nathalie, Lübbert, Michael, Sapena, Rosa, Nimubona, Stanislas, Goasguen, Jean, Wattel, Eric, Zini, Gina, Torregrosa Diaz, Jose Miguel, Germing, Ulrich, Pelizzari, Anna Maria, Park, Sophie, Jaekel, Nadja, and Metzgeroth, Georgia

Published
2023
Full Text
View/download PDF

21. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL)

Author

Kchour, Ghada, Tarhini, Mahdi, Kooshyar, Mohamad-Mehdi, El Hajj, Hiba, Wattel, Eric, Mahmoudi, Mahmoud, Hatoum, Hassan, Rahimi, Hossein, Maleki, Masoud, Rafatpanah, Houshang, Rezaee, S.A. Rahim, Yazdi, Mojtaba Tabatabaei, Shirdel, Abbas, de Thé, Hugues, Hermine, Olivier, Farid, Reza, and Bazarbachi, Ali

Published
2009
Full Text
View/download PDF

22. A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher‐Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutations.

Author

Adès, Lionel, Duployez, Nicolas, Guerci‐Bresler, Agnes, Laribi, Kamel, Peterlin, Pierre, Vey, Norbert, Thepot, Sylvain, Wickenhauser, Stefan, Zerazhi, Hacene, Stamatoullas, Aspassia, Wattel, Eric, Recher, Christian, Toma, Andrea, Dimicoli‐Salazar, Sophie, Braun, Thorsten, Beyne‐Rauzy, Odile, Marolleau, Jean‐Pierre, Cheze, Stéphane, Park, Sophie, and Cluzeau, Thomas

Subjects
VALPROIC acid, SOMATIC mutation, LENALIDOMIDE, AZACITIDINE, IDARUBICIN, BLAST injuries
Abstract

In order to improve the outcome observed with azacitidine (AZA) in higher‐risk Myelodysplastic syndrome (MDS), its combination with other drugs in MDS must be evaluated. So far, no combination has not been shown to be more effective than AZA alone. AZA‐PLUS was a phase II trial that, in a "pick a winner" approach, randomly assigned patients with higher‐risk MDS, CMML and low blast count AML to: AZA; AZA plus lenalidomide; AZA plus Valproic Acid or AZA plus Idarubicin. 322 patients were included. After six cycles, 69 (21.4%) CR + PR were observed with no benefit from any combination. Median EFS and OS were 17.2 and 19.7 months in the whole cohort, respectively, with no difference across randomised arms. Infection and rates of hospitalisation during the first six cycles were higher in the AZA‐LEN And AZA‐IDA arm, related to increased myelosuppression. Factors associated with better response were IPSS, favourable or intermediate karyotype, haemoglobin, lower circulating blast count, fibrinogen level and lower LDH, while poorer survival was seen in therapy‐related MDS and, in the case of TP53, PTPN11 or CSF3R mutation. The combinations used did not improve the outcome obtained with AZA alone. However, our "pick a winner" randomised strategy may remain useful with potentially more active drugs to be tested in combination with AZA. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

23. Prognostic Index for Older Adult Patients with Newly Diagnosed Acute Myeloid Leukemia: The Edouard Herriot Hospital Experience

Author

Plesa, Claudiu, Le, Quoc-Hung, Chelghoum, Youcef, Elhamri, Mohamed, Tigaud, Isabelle, Anglaret, Bruno, Ducastelle, Sophie, Perrin, Marie-Claire, Nicolini, Franck, Belhabri, Amine, Troncy, Jacques, Thiebaut, Anne, Hayette, Sandrine, Revesz, Daniella, Wattel, Eric, Dumontet, Charles, Michallet, Mauricette, and Thomas, Xavier

Published
2008
Full Text
View/download PDF

27. Immunohistochemical and virological features of HTLV-1-associated myosites: a study of 13 patients from West Indies and Africa

Author

Martin-Latil Sandra, Bassot Sylviane, Khun Huot, Cumont Marie-Christine, Huerre Michel, Wattel Eric, Mortreux Franck, Morin Anne-Sophie, Texeira Antonio, Chérin Patrick, Haroche Julien, Amoura Zahir, Lacour Arnaud, Papo Thomas, Marcorelles Pascale, Zagnoli Fabien, Penisson-Besnier Isabelle, Mikol Jacqueline, Polivka Marc, Hermine Olivier, Aouba Achille, Desrames Alexandra, Maisonobe Thierry, Cassar Olivier, Desdouits Marion, Taylor Graham, Gessain Antoine, Ozden Simona, and Ceccaldi Pierre-Emmanuel

Subjects
Immunologic diseases. Allergy, RC581-607
Published
2011
Full Text
View/download PDF

43. Tax gene expression and cell cycling but not cell death are selected during HTLV-1 infection in vivo

Author

Pinatel Christiane, Gout Olivier, Gessain Antoine, Delfau-Larue Marie-Hélène, Zandecki Marc, Jeannin Lionel, Sibon David, Zane Linda, Lançon Agnès, Mortreux Franck, and Wattel Eric

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Adult T cell leukemia results from the malignant transformation of a CD4+ lymphoid clone carrying an integrated HTLV-1 provirus that has undergone several oncogenic events over a 30-60 year period of persistent clonal expansion. Both CD4+ and CD8+ lymphocytes are infected in vivo; their expansion relies on CD4+ cell cycling and on the prevention of CD8+ cell death. Cloned infected CD4+ but not CD8+ T cells from patients without malignancy also add up nuclear and mitotic defects typical of genetic instability related to theexpression of the virus-encoded oncogene tax. HTLV-1 expression is cancer-prone in vitro, but in vivo numerous selection forces act to maintain T cell homeostasis and are possibly involved in clonal selection. Results Here we demonstrate that the HTLV-1 associated CD4+ preleukemic phenotype and the specific patterns of CD4+ and CD8+ clonal expansion are in vivo selected processes. By comparing the effects of recent (1 month) experimental infections performed in vitro and those observed in cloned T cells from patients infected for >6-26 years, we found that in chronically HTLV-1 infected individuals, HTLV-1 positive clones are selected for tax expression. In vivo, infected CD4+ cells are positively selected for cell cycling whereas infected CD8+ cells and uninfected CD4+ cells are negatively selected for the same processes. In contrast, the known HTLV-1-dependent prevention of CD8+ T cell death pertains to both in vivo and in vitro infected cells. Conclusions Therefore, virus-cell interactions alone are not sufficient to initiate early leukemogenesis in vivo.

Published
2010
Full Text
View/download PDF

45. A dose-effect relationship for deltaretrovirus-dependent leukemogenesis in sheep

Author

Wattel Eric, Willems Lucas, Kerkhofs Pierre, Lançon Agnes, Debacq Christophe, Alcaraz Maria, Pomier Carole, and Mortreux Franck

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Retrovirus-induced tumors develop in a broad range of frequencies and after extremely variable periods of time, from only a few days to several decades, depending mainly on virus type. For hitherto unexplained reasons, deltaretroviruses cause hematological malignancies only in a minority of naturally infected organisms and after a very prolonged period of clinical latency. Results Here we demonstrate that the development of malignancies in sheep experimentally infected with the deltaretrovirus bovine leukemia virus (BLV) depends only on the level of BLV replication. Animals were experimentally infected with leukemogenic or attenuated, but infectious, BLV molecular clones and monitored prospectively through 8 months for viral replication. As early as 2 weeks after infection and subsequently at any time during follow-up, leukemogenic viruses produced significantly higher absolute levels of reverse transcription (RT), clonal expansion of infected cells, and circulating proviruses with RT- and somatic-dependent mutations than attenuated viruses. These differences were only quantitative, and both kinds of viruses triggered parallel temporal fluctuations of host lymphoid cells, viral loads, infected cell clonality and proliferation. Conclusion Deltaretrovirus-associated leukemogenesis in sheep appears to be a two-hit process over time depending on the amounts of first horizontally and then vertically expanded viruses.

Published
2009
Full Text
View/download PDF

46. Early and transient reverse transcription during primary deltaretroviral infection of sheep

Author

Wattel Eric, Willems Lucas, Kerkhofs Pierre, Lançon Agnes, Debacq Christophe, Alcaraz Maria, Pomier Carole, and Mortreux Franck

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Intraindividual genetic variability plays a central role in deltaretrovirus replication and associated leukemogenesis in animals as in humans. To date, the replication of these viruses has only been investigated during the chronic phase of the infection when they mainly spread through the clonal expansion of their host cells, vary through a somatic mutation process without evidence for reverse transcriptase (RT)-associated substitution. Primary infection of a new organism necessary involves allogenic cell infection and thus reverse transcription. Results Here we demonstrate that the primary experimental bovine leukemia virus (BLV) infection of sheep displays an early and intense burst of horizontal replicative dissemination of the virus generating frequent RT-associated substitutions that account for 69% of the in vivo BLV genetic variability during the first 8 months of the infection. During this period, evidence has been found of a cell-to-cell passage of a mutated sequence and of a sequence having undergone both RT-associated and somatic mutations. The detection of RT-dependent proviral substitution was restricted to a narrow window encompassing the first 250 days following seroconversion. Conclusion In contrast to lentiviruses, deltaretroviruses display two time-dependent mechanisms of genetic variation that parallel their two-step nature of replication in vivo. We propose that the early and transient RT-based horizontal replication helps the virus escape the first wave of host immune response whereas somatic-dependent genetic variability during persistent clonal expansion helps infected clones escape the persistent and intense immune pressure that characterizes the chronic phase of deltaretrovirus infection.

Published
2008
Full Text
View/download PDF

48. Decitabine Versus Hydroxyurea for Advanced Proliferative CMML: Results of the Emsco Randomized Phase 3 Dacota Trial

Author

Itzykson, Raphael, Santini, Valeria, Chaffaut, Cendrine, Lionel, Ades, Thepot, Sylvain, Giagounidis, Aristoteles, Morabito, Margot, Droin, Nathalie, Luebbert, Michael, Sapena, Rosa, Nimubona, Stanislas, Goasguen, Jean E., Wattel, Eric, Zini, Gina, Torregrosa Diaz, Jose Miguel, Germing, Ulrich, Pelizzari, Anna Maria, Park, Sophie, Jaekel, Nadja, Metzgeroth, Georgia, Onida, Francesco, Navarro, Robert, Patriarca, Andrea, Stamatoulas Bastard, Aspasia, Puttrich, Martin, Mossuto, Sandra, Solary, Eric, Gloaguen, Silke, Chevret, Sylvie, Chermat, Fatiha, Platzbecker, Uwe, and Fenaux, Pierre

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results